KingMed Diagnostics
KingMed Diagnostics is China's largest independent third-party medical testing and pathology diagnostic services provider, serving 23,000+ medical institutions across all 31 provinces with 4,300+ testing items, anchored by a proprietary AI platform built on 30PB of medical testing data.
- Company typePublic
- Founded1994
- HeadquartersGuangzhou, China
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What KingMed Diagnostics does
KingMed Diagnostics (金域医学, SSE: 603882) is China's largest independent third-party medical testing and pathology diagnostic services provider, founded in 1994 and headquartered in Guangzhou. The company operates a nationwide service network spanning all 31 Chinese provinces plus Hong Kong, comprising 700+ co-built regional testing and pathology diagnosis centers and serving 23,000+ medical institutions ranging from tertiary hospitals to township health centers. Its core offering provides access to 4,300+ clinical testing items across multiple technology platforms including genomics, mass spectrometry, pathology, immunology, and molecular diagnostics, supported by wholly-owned subsidiaries for cold chain logistics (Kingda Logistics), forensic identification, health checkups, sanitation testing (Jinzhi Testing), and clinical trials support.
The company's revenue model is anchored in B2B clinical testing services priced on a quote/transaction basis to healthcare institutions, with diversified supplementary streams including health management subscriptions, clinical trials services, cold chain logistics, and data product monetization through 38+ listings on Beijing, Shanghai, and Guangzhou data exchanges. Distribution runs through a direct enterprise sales model with regional offices and field sales teams targeting hospital administrators and clinical departments across all healthcare system levels.
KingMed has built a vertically integrated AI stack atop its 30PB+ proprietary medical testing dataset, anchored by the Yujian Yuyan LLM (industry-first medical testing vertical LLM, August 2024) and 60+ intelligent agents under the Small Domain Medical (小域医) series. Strategic technology partnerships include Tencent (DeepGEM pathology-genomics multimodal model), Huawei Cloud (Yujian Yuyan All-in-One Machine), and China Unicom Smart Medical (AI Doctor system), with co-development of clinical AI alongside top academic hospitals including Guangzhou Medical University First Affiliated Hospital, Peking University Third Hospital, and Zhongshan Third Hospital. Notable differentiators include selection as the only medical institution in the National Data Bureau's first batch of trusted data space innovation pilots, DCMM Level 3 certification (first in the medical testing sector), and National Intellectual Property Demonstration Enterprise status (2019).
KingMed Diagnostics firmographics
Firmographics- Name
- KingMed Diagnostics
- Legal name
- Guangzhou Kingmed Medical Laboratory Group Co., Ltd. (广州金域医学检验集团股份有限公司)
- Website
- https://kingmed.com.cn
- Company type
- Public
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- KingMed Diagnostics is China's largest independent third-party medical testing and pathology diagnostic services provider, serving 23,000+ medical institutions across all 31 provinces with 4,300+ testing items, anchored by a proprietary AI platform built on 30PB of medical testing data.
- Ownership category
- akta.pro rank
KingMed Diagnostics industry classification
Industry- Product category
- Clinical Laboratory and Pathology Diagnostic Services
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)
- akta.pro secondary industries
- Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)
Keywords
Where KingMed Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Guangzhou
- HQ country
- China
- HQ region
- Asia
Offices10 records
Markets served
KingMed Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Clinical Testing and Pathology Diagnostic Services: Core revenue stream from providing medical testing services to hospitals and healthcare institutions. Services include clinical diagnosis information services, disease specialist alliances, and comprehensive laboratory solutions for medical institutions at all levels.
- New Health Management Services: Integrated health management solutions for public health, research, insurance and other industries, providing comprehensive health management services.
- Data Product Sales: 21+ data products listed on Beijing, Shanghai, and Guangzhou data exchanges covering infection, tumor, neurology, and genetics domains. Revenue generated from selling data analytics reports and algorithm models to pharma companies, CDC, and insurance firms.
- Cold Chain Logistics (金域达物流): Professional medical cold chain logistics services supporting sample transportation for testing operations.
- Clinical Trials Services: Clinical trial support services for pharmaceutical companies and medical institutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Clinical testing services - quote-based pricing for institutional clients |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
KingMed Diagnostics product offering
Product offeringCore offering
KingMed Diagnostics is China's leading independent third-party medical laboratory and pathology diagnostics provider, offering over 4,300 clinical testing and pathology diagnostic items to more than 23,000 medical institutions across all 31 provinces and Hong Kong. The company provides clinical diagnosis information services, disease specialist alliances, laboratory overall solutions (from design to operation), new health management services, and a growing portfolio of AI-powered diagnostic products including the Yujian Yuyan Medical LLM, Small Domain Medical AI agents, and AI-driven smart laboratory workstations.
Product overview
KingMed Diagnostics operates as a comprehensive medical examination and pathology diagnostics platform with a 'platform + module' architecture. The core offering includes clinical diagnosis information services integrating multiple technology platforms (genomics, mass spectrometry, pathology, immunology) providing over 4,300 testing items. The company has developed an AI ecosystem anchored by the '域见医言大模型' (Yujian Yuyan Medical LLM) - the industry's first medical examination vertical large language model - and its associated '小域医' (Small Domain Medical) AI agent series with 60+ intelligent agents. Supporting infrastructure includes the AI开放创新平台 (AI Open Innovation Platform) for external AI development, the 医检可信数据空间 (Trusted Medical Data Space) for secure data exchange, and 金域云检KMC customer service platform. The company also offers integrated solutions including laboratory design and management, health management services, cold chain logistics, forensic identification, sanitation testing, and health examinations. Services are delivered through a nationwide service network covering 31 provinces and serving 23,000+ medical institutions annually.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Diagnosis Information Services (临床诊断信息服务) Comprehensive clinical diagnosis information services integrating multiple technology platforms (genomics, mass spectrometry, pathology, immunology) and testing methods to help clinical doctors make accurate diagnoses across oncology, genetics, infectious diseases, and rare diseases.
- Yujian Yuyan Medical LLM (域见医言大模型) Industry's first medical examination vertical domain large language model providing intelligent medical services including report interpretation, diagnosis assistance, and health management by leveraging 30+ years of medical examination data and knowledge.
- Small Domain Medical AI Agent Series (小域医) AI agent application series providing intelligent services including test project recommendations, report interpretation, disease diagnosis assistance, medication support, and health checkup report generation for doctors and patients.
- AI Open Innovation Platform (AI开放创新平台) AI development and deployment platform enabling external developers and partners to build medical AI applications on KingMed's infrastructure and medical data capabilities.
- Trusted Medical Examination Data Space (医检可信数据空间) Trusted medical examination data exchange platform facilitating secure circulation and collaboration of medical data. Named as national first batch trusted data space innovation pilot by the National Data Bureau.
- Smart Laboratory Solutions (智慧实验室)
- KingMed Cloud Check KMC (金域云检KMC)
- Overall Laboratory Solutions (整体解决方案)
- New Health Management Services (新型健康管理)
- Cold Chain Logistics (冷链物流)
- Sanitation Testing (卫生检验)
- Forensic Identification (司法鉴定)
- Health Examination (健康体检)
- Clinical Testing Services (临床检测)
- Disease Specialist Alliances (疾病专科联盟)
- Data Element Services (数据要素×)
- DeepGEM Pathological-Genomic Multimodal Model AI model jointly developed with Tencent that predicts lung cancer gene mutations from routine histopathological images with 78%-99% accuracy in 1 minute, potentially reducing gene detection costs by over 80%.
- AI Doctor System (Zhongshan Third Hospital AI Doctor) AI doctor platform jointly developed with Zhongshan Third Hospital and China Unicom Smart Medical, covering the full symptom-exam-diagnosis-treatment-followup chain for clinical decision support.
Quantifiable outcome
- AI-assisted cervical cancer screening efficiency improved 4x while maintaining quality standards
- +4 more outcomes
Companies that use KingMed Diagnostics
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles4 records
KingMed Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability11 records
Feature6 records
KingMed Diagnostics partnerships and signals
Strategic signalPartnerships
24 partnerships are on record, tiered major, core and minor.
- Shanghai Tongkang Hospital (上海同康医院)majorStrategic cooperation framework agreement to build integrated smart medical service system, focusing on elderly care, tumor, infection, and neuroimmune diseases.
- Peking University Third Hospital (北京大学第三医院)coreJointly established Beijing Key Laboratory for Neurological Rare Diseases Innovation Diagnosis and Transformation. Research focuses on ALS, CMT and other neurological rare diseases.
- Humana Healthcare (和睦家医疗)coreStrategic cooperation in International Oncology Center, high-end health management, and brain health. Focus on precision testing services and clinical application scenarios.
- Guangzhou Medical Health AI Industry Alliance (广州医疗健康人工智能产业联盟)majorCo-founded alliance with Guangzhou National Laboratory, universities, research hospitals, and tech companies to advance medical AI industry development in Guangzhou.
- Henan University of Traditional Chinese Medicine (河南中医药大学)majorJoint establishment of provincial graduate training workstation with Zhengzhou KingMed. Focus on digital medical testing talent cultivation and AI-enabled testing education.
- World Data Organization (WDO)majorFirst member from medical testing industry. WDO aims to bridge data gaps, unlock data value, and prosper digital economy across 40+ countries.
- China Kidney Pathology Collaboration Network (中国肾脏病理协作网)majorCore support unit for collaboration network initiated by Fudan University Zhongshan Hospital. Covers nearly 30 provinces with focus on standardizing kidney pathology diagnosis.
- Gilead Sciences (吉利德科学)majorJoint hepatitis C free screening campaign covering 25 provinces and nearly 200 medical institutions, donating 10,000+ screening tests.
- Guangzhou Women and Children's Medical Center (广妇儿)coreCo-founded Birth Defect Prevention and Control Specialty Alliance. 10 provinces, nearly 60 medical institutions, 60,000+ tests performed.
- Nanjing Vazyme (南京诺唯赞)majorStrategic cooperation in nervous system disease detection. Focus on AD biomarker detection technology R&D, clinical verification, and market promotion. Build 'technology R&D-clinical verification-market promotion' closed loop.
- Guangxi Medical University (广西医科大学)majorStrategic cooperation for digital medical and health ecosystem. Jointly build multimodal specialist disease diagnosis models and intelligent agents, establish 'R&D-verification-transformation' closed loop.
- Fengkai County Government (封开县人民政府)majorDeployment of Guangdong Province's first county-level AI-assisted diagnosis platform covering 19 county and township hospitals, serving 500,000 residents.
- Zhongshan Third Hospital (中山大学附属第三医院)coreJoint release of AI Doctor system and establishment of Medical Data Intelligence Joint Laboratory. Hospital provides clinical expertise and de-identified diagnosis data for training.
- China Unicom Smart Medical (联通数智医疗)majorJoint development of AI Doctor system. Provides digital infrastructure, computing power, and system integration capabilities.
- Henan Allergy Disease Collaboration Network (河南省过敏性疾病精准诊疗与临床研究协作网)minorJoined as technical support unit providing precision allergy testing services. Network covers 13 medical institutions.
- Guilin Medical University (桂林医科大学)majorJoint establishment of Guangxi multimodal biomarker and precision diagnosis key laboratory with Guangxi KingMed and Guilin Youlitu. Develop multi-modal biomarker systems for tumor, genetic rare disease, and cross-border infectious disease.
- Yunnan Allergy Diagnosis and Treatment Alliance (云南省变态反应诊治联盟)minorJoined as technical cooperation unit providing standardized allergy disease testing services. Alliance covers 18 hospitals.
- China Prion Disease Alliance (中国朊蛋白病联盟)minorJoined as standardized public testing service platform. Provides standardized nervous system and prion disease testing services using RT-QuIC technology.
- Tencent (腾讯)coreJoint development of DeepGEM pathological-genetic multimodal model with Guangzhou Medical University First Affiliated Hospital. Tencent provides AI technology including multi-instance learning (MIL) and end-to-end architecture. Model predicts lung cancer gene mutations from routine pathology images with 78%-99% accuracy.
- Guangzhou Medical University First Affiliated Hospital / National Respiratory Medicine Center (广州医科大学附属第一医院/国家呼吸医学中心)coreJoint development of DeepGEM model with He Jianxing/Liang Wenhua team. Hospital provides clinical expertise and validation data from 4,260 lung cancer patient samples across 30 provinces.
- Nanpi County People's Hospital (南皮县人民医院)majorCo-built regional testing center serving county-township-village three-level coordination network. Connected 70 village clinics with nearly 200 specimens processed.
- Beijing International Big Data Exchange, Shanghai Data Exchange, Guangzhou Data Exchangemajor21+ data products listed on these exchanges for compliant medical data circulation to pharma, insurance, and research institutions.
- Guangzhou Medical University (广州医科大学)coreCo-founded 金域检验学院 with joint curriculum development. Clinical Chromatography Mass Spectrometry Testing Technology course awarded national first-class undergraduate course; Clinical Genomics Testing textbook won provincial excellent textbook award.
- Huawei (华为)majorJointly developed four 'DomainSee Large Model All-in-One Machine' products with Huawei Cloud. Deployed cervical cancer cell AI-assisted screening model improving efficiency 4x.
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
KingMed Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory services companies globally, operating a reference lab network similar in concept to KingMed. While geographically separate, the business model of high-volume routine and specialty testing for healthcare providers is directly analogous.
- Eurofins Scientific: Eurofins is a global leader in bioanalytical testing with clinical diagnostics operations. Comparable to KingMed for its clinical reference laboratory services, bioanalytical testing capabilities, and global footprint in medical testing markets.
- Mindray Medical: Mindray is China's largest medical device and IVD instrumentation company, providing in-vitro diagnostic equipment and reagents. It is comparable to KingMed through its IVD reagent business and laboratory automation solutions sold to Chinese hospitals.
- Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory network offering routine, esoteric, and anatomic pathology testing to healthcare providers. Comparable to KingMed as a B2B-focused reference lab with broad test menus and extensive logistics infrastructure.
Direct peers
- Da An Gene (Da An Health): Da An Gene is a major Chinese molecular diagnostics company, particularly strong in infectious disease testing and clinical molecular diagnostics. It is comparable to KingMed in clinical PCR and molecular testing service offerings.
- BGI Genomics: BGI Genomics is a leading Chinese genetic testing and genomics company that overlaps with KingMed in molecular diagnostics, NGS-based testing, and genetic disease screening services. Both serve hospital and clinical customers with advanced genetic testing capabilities.
- DiAn Diagnostics: DiAn Diagnostics is one of China's largest third-party medical laboratory service providers and KingMed's most direct domestic competitor. Both companies operate nationwide lab networks serving hospitals, offer similar testing menus, and compete for the same B2B medical institution clients across China.
- ADICON Laboratories: ADICON is another major Chinese independent clinical laboratory company with comparable geographic coverage and service offerings. It competes directly with KingMed in routine and specialty testing services for hospitals and medical institutions.
Emerging players
- Guardant Health: Guardant Health is a leading precision oncology company using liquid biopsy and genomics for cancer detection. Comparable to KingMed's advanced oncology diagnostics (ctDNA NGS standards leadership) and AI-enabled cancer mutation prediction capabilities.
- Tempus AI: Tempus AI is a technology-enabled precision medicine company applying AI to molecular and clinical data. Comparable to KingMed's data and AI strategy (DomainSee LLM, DeepGEM multimodal model) for clinical decision support and data-driven diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
KingMed Diagnostics social profiles
Digital presenceKingMed Diagnostics compliance and trust
Trust signalCompliance7 records
KingMed Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
KingMed Diagnostics leadership team
Management profileNumber of profiles
Profiles9 records
KingMed Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries6 records
KingMed Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KingMed Diagnostics M&A and investment
M&A and investmentM&A
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KingMed Diagnostics
What does KingMed Diagnostics do?
KingMed Diagnostics is China's leading independent third-party medical laboratory and pathology diagnostics provider, offering over 4,300 clinical testing and pathology diagnostic items to more than 23,000 medical institutions across all 31 provinces and Hong Kong. The company provides clinical diagnosis information services, disease specialist alliances, laboratory overall solutions (from design to operation), new health management services, and a growing portfolio of AI-powered diagnostic products including the Yujian Yuyan Medical LLM, Small Domain Medical AI agents, and AI-driven smart laboratory workstations.
Is KingMed Diagnostics a public or private company?
KingMed Diagnostics is a public company. It is classified as public and is currently operating.
When was KingMed Diagnostics founded?
KingMed Diagnostics was founded in 1994. It employs 5,001 to 10,000 people.
Where is KingMed Diagnostics based?
KingMed Diagnostics is headquartered in Guangzhou, China, in the Asia region.
How does KingMed Diagnostics make money?
Five revenue lines are on record. Clinical Testing and Pathology Diagnostic Services are the primary driver. The others are new Health Management Services, data Product Sales, cold Chain Logistics (金域达物流) and clinical Trials Services.
Who are KingMed Diagnostics's main competitors?
Broad incumbents on record are Quest Diagnostics, Eurofins Scientific, Mindray Medical and Laboratory Corporation of America (Labcorp). Direct peers are Da An Gene (Da An Health), BGI Genomics, DiAn Diagnostics and ADICON Laboratories. Emerging players are Guardant Health and Tempus AI.
Does KingMed Diagnostics have an API?
No public API is recorded for KingMed Diagnostics.
What industry is KingMed Diagnostics in?
KingMed Diagnostics's product category is Clinical Laboratory and Pathology Diagnostic Services. Its primary akta.pro industry code is HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics), with a secondary code of HLAAALAI, Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays). Its NAICS code is 62151 and its SIC code is 8071.